scholarly journals Small RNA-mediated genomic silencing promotes telomere stability in the absence of telomerase

2018 ◽  
Author(s):  
Charlie Longtine ◽  
Stephen Frenk ◽  
Shawn Ahmed

AbstractTelomerase deficiency in human somatic cells results in telomere erosion and senescence. Small RNAs that target telomeres have been observed in diverse organisms but their functions are not well characterized. We define an endogenous small RNA pathway in Caenorhabditis elegans that promotes heterochromatin formation at telomeres via Dicer, the perinuclear Argonaute protein WAGO-1 and the nuclear Argonaute protein HRDE-1. Loss of telomerase induces biogenesis of siRNAs that target the telomeric lncRNA TERRA, whereas loss of both telomerase and small RNA-mediated telomeric silencing induces TERRA expression, DNA damage, and an accelerated sterility phenotype. These phenotypes can be rescued by exogenous telomeric siRNAs or by loss of the DNA damage response protein EXO-1. Thus, endogenous siRNAs interact with TERRA to promote heterochromatin formation in a manner that is critical for the stability of naturally eroding telomeres. We propose that small RNA-mediated genome silencing could be broadly relevant to regulation of proliferative aging.

2017 ◽  
Vol 233 (4) ◽  
pp. 2781-2790 ◽  
Author(s):  
Matthias Rieckher ◽  
Arturo Bujarrabal ◽  
Markus A. Doll ◽  
Najmeh Soltanmohammadi ◽  
Björn Schumacher

DNA Repair ◽  
2007 ◽  
Vol 6 (3) ◽  
pp. 329-343 ◽  
Author(s):  
Jean-François St-Laurent ◽  
Steve N. Gagnon ◽  
Florence Dequen ◽  
Isabelle Hardy ◽  
Serge Desnoyers

2007 ◽  
Vol 178 (5) ◽  
pp. 887-887
Author(s):  
Antonia H. Holway ◽  
Seung-Hwan Kim ◽  
Adriana La Volpe ◽  
W. Matthew Michael

PLoS Genetics ◽  
2010 ◽  
Vol 6 (12) ◽  
pp. e1001227 ◽  
Author(s):  
James F. Theis ◽  
Carmela Irene ◽  
Ann Dershowitz ◽  
Renee L. Brost ◽  
Michael L. Tobin ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6008
Author(s):  
Nura Lutfi ◽  
Miguel Alejandro Galindo-Campos ◽  
José Yélamos

The DNA damage response (DDR) maintains the stability of a genome faced with genotoxic insults (exogenous or endogenous), and aberrations of the DDR are a hallmark of cancer cells. These cancer-specific DDR defects present new therapeutic opportunities, and different compounds that inhibit key components of DDR have been approved for clinical use or are in various stages of clinical trials. Although the therapeutic rationale of these DDR-targeted agents initially focused on their action against tumour cells themselves, these agents might also impact the crosstalk between tumour cells and the immune system, which can facilitate or impede tumour progression. In this review, we summarise recent data on how DDR-targeted agents can affect the interactions between tumour cells and the components of the immune system, both by acting directly on the immune cells themselves and by altering the expression of different molecules and pathways in tumour cells that are critical for their relationship with the immune system. Obtaining an in-depth understanding of the mechanisms behind how DDR-targeted therapies affect the immune system, and their crosstalk with tumour cells, may provide invaluable clues for the rational development of new therapeutic strategies in cancer.


RSC Advances ◽  
2017 ◽  
Vol 7 (52) ◽  
pp. 32624-32631 ◽  
Author(s):  
Yun Wang ◽  
Lianfeng Zhang ◽  
Xun Luo ◽  
Shunchang Wang ◽  
Yuanyuan Wang

Bisphenol A can trigger germline apoptosis via three signaling pathways including DNA damage response (DDR) pathway, mitogen-activated protein kinase (MAPK) cascades and insulin-like growth factor-1 (IGF-1) network in Caenorhabditis elegans.


Sign in / Sign up

Export Citation Format

Share Document